Assessing Tablet-Sticking Propensity - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Assessing Tablet-Sticking Propensity
The authors designed an upper punch with a removable punch tip to determine a tablet formulation's propensity to stick by weighing the mass of powder adhered to the punch tip.


Pharmaceutical Technology
Volume 36, Issue 1, pp. 57-62


Figure 7: Sticking profiles for prototype and commercially available ibuprofen formulations.
Benchmarking sticking of a new ibuprofen formulation. A prototype ibuprofen formulation was tested alongside three commercially available ibuprofen formulations to quantify sticking risk before scale-up. The prototype formulation contained a 50% w/w level of ibuprofen and 5% w/w talc as the tableting lubricant. After 100 compressions, the prototype formulation had about 1500 g of powder adhered to the punch tip. The commercial ibuprofen formulations had lower sticking: Albemarle had the most, followed by BASF and Advil (See Figure 7). Using Advil as the gold-standard benchmark, the prototype formulation was deemed to be unsuitable for product scale-up without reformulation. The high level of sticking for the prototype ibuprofen formulation was attributed to literature reports of talc as a suboptimal tableting lubricant for sticky formulations (7, 8), in addition to ibuprofen's notorious propensity to stick. This quantitative assessment shows the benefit of testing prototype formulations and benchmarking alongside formulations known to (or not to) exhibit sticking behavior. Thus, unsuitable formulations can be flagged quickly during drug product design.

Conclusion

The simple method of using a removable punch tip is capable of quantitatively measuring sticking for formulations containing various levels of tableting lubricant and various grades and concentrations of sticky ingredients. This tool can be used to screen tableting formulations during drug-product design to optimize formulation composition, and potentially to study the effect of sticking on tableting process parameters (e.g., tableting speed and compression force) and tooling design features (e.g., metal composition, surface roughness, shape, curvature, and embossing).

Acknowledgments

The authors thank MDC Associates for assisting with the design and fabrication of the custom punch. They thank Gregory (Scott) Goeken, scientist, and John Kresevic, senior principal scientist, both at Pfizer, for providing the prototype and commercial ibuprofen formulation samples.

References

1. M. Roberts et al., J. Pharm. Pharmacol. 56 (3), 299–305 (2004).

2. T.S. McDermott et al., Powder Technol. 212 (1), 240–252 (2011).

3. D. Simmons, poster at the 12th Annual American Association of Pharmaceutical Scientists—Northeast Regional Discussion Group (Rocky Hill, CT, 2009).

4. J.J. Wang et al., J. Pharm. Sci. 93 (2), 407–417 (2004).

5. Y. Cheng et al., Proceedings of AICHE Annual Conference (Orlando, FL, 2006), pp. 1–13.

6. F. Waimer et al., Pharm. Dev. Technol. 4 (3), 359–367 (1999).

7. M. Bose, A. Sakr, and A. Warner, Pharm. Industrie 55 (5), 519–522 (1993).

8. A. Delacourte et al., Drug Dev. Ind. Pharm. 19 (9), 1047–1060 (1993).

What would you do differently? Email your thoughts about this paper to
and we may post them on http://PharmTech.com/.

Matthew P. Mullarney* is a principal scientist, Bruce C. MacDonald is a scientist, and Allan Hutchins is a laboratory technician, all at Pfizer, Eastern Point Road, Groton, CT 06340, tel. 860.715.4139, fax 860.441.3972,
.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here